The GLP-1 story shows how patents can reward discovery and push rivals to develop better drugs.
GLP-1s
Our Noom GLP-1 review covers Noom Med’s costs, medications, coaching, pros and cons, and what to know...
Denmark's national bank cited Novo Nordisk demand in the US as a driver of GDP growth.
“I'm obese, morbidly obese, BMI 42. I had quadruple heart bypass surgery. I'm at risk for stroke....
Wells Fargo Industry Insights' Robin Wenzel says the drugs are rewriting healthcare economics, but the math doesn't...
There's something the tens of millions of Americans who are currently on GLP-1 medications, or thinking of starting them, need to know.
Tens of millions of Americans are eating less meat and sugar on GLP-1s. The climate math behind...